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PCV81 DISCRETE EVENT SIMULATION OF LONG-TERM HEALTH BENEFITS AND COST-EFFECTIVENESS OF IMPLANTING DUAL CHAMBER VS. SINGLE CHAMBER VENTRICULAR PACEMAKERS IN ITALY
Ward AJ, Caro JJ, Deniz HB Caro Research Institute, Concord, MA, USA OBJECTIVE: To estimate the long-term economic and health impact of managing bradycardia due to sinoatrial node disease or atrioventricular block with a dual (DDD or DDDR) vs. single chamber ventricular pacemaker (VVI or VVIR). METHODS: A discrete event simulation was constructed to evaluate the outcomes over five years. During the simulation, each patient may develop post-operative complications, severe pacemaker syndrome leading to replacement of the VVI(R) with DDD(R), atrial fibrillation (which may become chronic and require anticoagulants), or have a stroke. A time for each event is sampled from the distribution of failure times specified by the individual's risk profile. Life expectancy was estimated and assumed the same with either device. Model risk functions are based on long-term randomized trials (Canadian Trial of Physiological Pacing and Mode Selection Trial in Sinus-Node Dysfunction). Probabilistic sensitivity analyses were performed for key input parameters. Direct medical costs are reported in 2004 Euros (€). Benefits and costs are discounted at 3% per year. RESULTS: Chronic atrial fibrillation was estimated to be 24% lower with DDD(R). Discounted costs over 5 years were about €10,000 per patient in either cohort, mean net additional cost of €106 with DDD(R). DDD(R) led to 0.09 additional QALY; a mean cost-effectiveness ratio of €1177/QALY, with 21% of replications indicating dominance for DDD(R). Severe pacemaker syndrome requiring switch to DDD(R) occurred in 16.8% with VVI(R); the results are sensitive to the proportion that would seek replacement. CONCLUSION: Lower initial costs with VVI(R) were offset by second operations to switch to DDD(R) and costs of atrial fibrillation. Thus, dual chamber pacemakers are economically attractive in management of patients with bradycardia.
PCV82 COST-UTILITY OF CILOSTAZOL FOR THE TREATMENT OF INTERMITTENT CLAUDICATION IN SCOTLAND
Ratcliffe A Abacus International, Bicester, Oxfordshire, UK OBJECTIVES: To evaluate short-term cost-effectiveness (costutility) of cilostazol for the treatment of intermittent claudication from the perspective of the Scottish NHS. METHODS: A decision analytic model was constructed and analysed from the perspective of the Scottish NHS. Costs include direct medical costs including drug costs -evaluated at retail prices excluding taxes, and treatment costs. Treatment costs included the cost of primary and specialist care of intermittent claudication patients based on an independent survey of expert clinical opinion in Scotland. Short-term effectiveness was based on two published 24 week randomised clinically controlled trials of cilostazol (100 mg) versus placebo. Placebo was chosen as the comparator since the majority of patients in Scotland do not currently receive intermittent claudication-specific medical treatment. Healthrelated quality of life was measured in the trials using the SF-36; these scores were translated into utilities using a validated mapping algorithm. QALYs were estimated over various scenarios including the base-case analysis of the most conservative assumption of immediate return to placebo utility post treatment. RESULTS: The incremental cost-utility ratio for cilostazol over placebo was estimated at approximately £12,500 per QALY. The data were not discounted due to the short time
